Featured CPE Activity
How Would You Treat This Patient?
Faculty Spotlight
“Response depth does not predict overall survival in Waldenstrom macroglobulinemia. This is not intuitive because response depth always predicts survival in myeloma and amyloidosis. . . Therefore, if you treat a patient and they failed to achieve a PR, that doesn’t mean they failed treatment; that doesn’t mean that you need to initiate second-line therapy. It depends on why you treated them in the first place.” - Morie Gertz, MACP
Morie Gertz, MD, is the Roland Seidler Jr. Professor in the Department of Medicine and Chair of General Internal Medicine at the Mayo Clinic in Rochester, Minnesota. He specializes in the treatment of patients with Waldenstrom macroglobulinemia, amyloidosis, and multiple myeloma, including those undergoing stem cell transplantation. Dr. Gertz serves as a member of the American Board of Internal Medicine’s Hematology Approval Committee, and he has authored or coauthored more than 700 manuscripts focusing on research for hematological malignancies.
Additional Resources
For additional information and unique perspectives on multiple myeloma treatment and patient care, check out the expert interviews listed below.
